WellDoc, a healthcare behavioral science and technology company that develops solutions aimed at engaging patients and enhancing health outcomes, has secured $20 million in funding from Merck Global Health Innovation Fund and Windham Venture Partners. For a limited time, WellDoc and its investors will also explore the possibility of adding co-investors that bring strategic value to the company.
The company's flagship product, BlueStar, is a patient-centered product cleared by the U.S. Food and Drug Administration in July 2010 for use by adults living with type 2 diabetes. The new product enables patients to self-manage their diabetes through real-time motivational, behavioral and educational coaching. It also coordinates care by helping patients adhere to their treatment plan while providing clinical decision support to the patient’s healthcare provider to optimize treatment decisions.